N/A N=93 Randomized Single-blind Health Services Research

Comparing 6-Minute Walk Tests for Ambulatory Oxygen Assessment

Respiratory Disease

Bottom Line

View on ClinicalTrials.gov: NCT05630092 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2026

Primary outcome: Primary: Average Drop in SpO2 From Baseline to Nadir — 6; 5 SpO2 (%) — p=<0.01

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Maximal 6-minute Walk Test (Max_6MWT) (Diagnostic_test); Normal speed 6-minute Walk Test (Nor_6MWT) (Diagnostic_test)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Hampshire Hospitals NHS Foundation Trust
Primary completion: Feb 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Average Drop in SpO2 From Baseline to Nadir	6; 5	<0.01 sig
SECONDARY Is There a Difference in the Time Taken to Reach Nadir in SpO2?	150; 150	0.50
SECONDARY Is There a Difference in the Nadir SpO2 (%) Between Maximal and Normal Walking Speed?	88.41; 88.98	<0.01 sig

Summary

Patients with lung disease who report breathlessness on exertion are often referred for a 6MWT. Due to the nature of the 6MWT (hereon referred to as a Max-6MWT), patients are required to walk as far as they can in 6 minutes. This may lead to an inaccurate assessment of their requirement for ambulatory oxygen as this form of exercise may not correspond to their normal daily activities. In this study, patients who are routinely referred for a Max-6MWT to investigate possible exercise-induced hypoxaemia will be invited to perform an additional walking test which is performed at their normal walking speed, referred here on in as a Nor\_6MWT. We hypothesise that performing a Nor\_6MWT will provide a more accurate assessment of a patients' oxygen requirement, primarily from their oxygen desaturation during the test.

Eligibility Criteria

Inclusion Criteria

Referred for a standard 6-minute walk test
Has the capacity to give informed consent
Is aged between 18 and 90

Exclusion Criteria

Lack of capacity to provide informed consent
Poor peripheral perfusion that prevents an accurate measurement of SpO2
Contraindicated to perform a Max\_6MWT as indicated in the standard HHFT 6MWT SO

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05630092). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.